BRPI0706947B8 - método de preparação de uma composição de micropartícula - Google Patents

método de preparação de uma composição de micropartícula

Info

Publication number
BRPI0706947B8
BRPI0706947B8 BRPI0706947A BRPI0706947A BRPI0706947B8 BR PI0706947 B8 BRPI0706947 B8 BR PI0706947B8 BR PI0706947 A BRPI0706947 A BR PI0706947A BR PI0706947 A BRPI0706947 A BR PI0706947A BR PI0706947 B8 BRPI0706947 B8 BR PI0706947B8
Authority
BR
Brazil
Prior art keywords
preparing
protein
microparticle composition
microspheres
solution
Prior art date
Application number
BRPI0706947A
Other languages
English (en)
Inventor
Fang Fang
P Malakhov Michael
Original Assignee
Ansun Biopharma Inc
Nexbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc, Nexbio Inc filed Critical Ansun Biopharma Inc
Publication of BRPI0706947A2 publication Critical patent/BRPI0706947A2/pt
Publication of BRPI0706947A8 publication Critical patent/BRPI0706947A8/pt
Publication of BRPI0706947B1 publication Critical patent/BRPI0706947B1/pt
Publication of BRPI0706947B8 publication Critical patent/BRPI0706947B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

método de preparação de uma composição à base de proteína, e, método de preparação de micropartículas baseadas em proteínas. as microesferas são produzidas ao entrar em contato com uma solução aquosa de uma proteína ou de outra macromolécula com um solvente orgânico e um contraíon e resfriar a solução. as microesferas são úteis para preparar produtos farmacêuticos de dimensões definidas.
BRPI0706947A 2006-01-24 2007-01-24 método de preparação de uma composição de micropartícula BRPI0706947B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76200206P 2006-01-24 2006-01-24
US60/762,002 2006-01-24
PCT/US2007/001914 WO2007114881A1 (en) 2006-01-24 2007-01-24 Technology for preparation of macromolecular microspheres

Publications (4)

Publication Number Publication Date
BRPI0706947A2 BRPI0706947A2 (pt) 2011-04-12
BRPI0706947A8 BRPI0706947A8 (pt) 2019-01-29
BRPI0706947B1 BRPI0706947B1 (pt) 2021-02-09
BRPI0706947B8 true BRPI0706947B8 (pt) 2021-05-25

Family

ID=38197716

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0706947A BRPI0706947B8 (pt) 2006-01-24 2007-01-24 método de preparação de uma composição de micropartícula

Country Status (13)

Country Link
US (7) US20070190163A1 (pt)
EP (1) EP1981483A1 (pt)
JP (2) JP5457680B2 (pt)
KR (5) KR101787939B1 (pt)
CN (2) CN101404980A (pt)
AU (1) AU2007233349A1 (pt)
BR (1) BRPI0706947B8 (pt)
CA (2) CA2639925C (pt)
HK (1) HK1210720A1 (pt)
IL (2) IL193001A (pt)
RU (2) RU2464973C2 (pt)
WO (1) WO2007114881A1 (pt)
ZA (1) ZA200807133B (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
CN1729013B (zh) * 2002-11-22 2012-10-03 耐百生物制药有限公司 广谱抗病毒化合物、药物制剂及其用途
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
EP1981483A1 (en) 2006-01-24 2008-10-22 Nexbio, Inc. Technology for preparation of macromolecular microspheres
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
AU2007297484B2 (en) * 2006-09-18 2013-07-18 Global Life Sciences Solutions Usa Llc Preparation of glassified biological reagents
CN103784408A (zh) * 2007-07-24 2014-05-14 安迅生物制药公司 用于制备微粒的技术
ES2394589T3 (es) 2007-12-14 2013-02-04 Aerodesigns, Inc Suministro de productos alimenticios transformables en aerosol
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
HUE054585T2 (hu) 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
SG10201507036TA (en) 2008-06-13 2015-10-29 Mannkind Corp A dry powder inhaler and system for drug delivery
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
EP2344196B1 (en) * 2008-09-12 2018-11-14 University Court of The University of St Andrews Carbohydrate binding molecules
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CN102665705A (zh) * 2009-01-22 2012-09-12 赛诺菲 包含非甾体抗炎药和秋水仙碱苷衍生物的活性成分的新组合
JP2013510169A (ja) * 2009-11-06 2013-03-21 ネクスバイオ，インク． 呼吸器管の治療及び予防のための方法、化合物、及び組成物
CA2783296C (en) 2009-12-15 2019-01-15 Ascendis Pharma As Growth hormone composition
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
NZ603136A (en) 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
DK2672986T3 (da) 2011-02-09 2020-06-08 Glaxosmithkline Llc Frysetørrede formuleringer
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
HK1200318A1 (en) 2011-10-24 2015-08-07 曼金德公司 Methods and compositions for treating pain
US9643996B2 (en) 2011-11-04 2017-05-09 Battelle Memorial Institute Processes for producing protein microparticles
US9034347B2 (en) * 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
WO2013096883A2 (en) * 2011-12-23 2013-06-27 The Regents Of The University Of California Spray dry method for encapsulation of biological moieties and chemicals in polymers cross-linked by multivalent ions for controlled release applications
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
CA2864746A1 (en) 2012-02-17 2013-08-22 Ansun Biopharma, Inc. Methods, compounds and compositions for treatment of influenza and parainfluenza patients
CA2872029A1 (en) 2012-05-29 2013-12-05 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
US20140154308A1 (en) * 2012-06-28 2014-06-05 Ansun Biopharma, Inc. Microparticle Formulations for Delivery to the Upper and Central Respiratory Tract and Methods of Manufacture
JP2015527310A (ja) 2012-06-28 2015-09-17 アンサン バイオファーマ, インコーポレイテッドAnsun Biopharma, Inc. 下気道および中枢気道への送達用微粒子製剤ならびに製造方法
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
EP2872205B1 (en) 2012-07-12 2017-02-08 MannKind Corporation Dry powder drug delivery systems
CN102757726B (zh) * 2012-08-07 2014-04-09 湖南罗比特化学材料有限公司 一种基于天然多羟基糖类制备的水性uv涂料及其方法
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
HK1218882A1 (zh) 2012-11-28 2017-03-17 Aphios Corporation 用於治疗神经退化疾病和其它疾病的组合治疗剂和方法
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
PE20151054A1 (es) 2012-12-17 2015-08-07 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN103109798B (zh) * 2013-02-26 2015-04-08 广州市锐博生物科技有限公司 壳聚糖纳米粒、防治红火蚁的生物农药制剂及其制备方法
CN103109800B (zh) * 2013-02-26 2015-04-08 广州市锐博生物科技有限公司 壳聚糖纳米粒、防治小菜蛾的生物农药制剂及其制备方法
CN103109799B (zh) * 2013-02-26 2015-04-08 广州市锐博生物科技有限公司 壳聚糖纳米粒、防治斜纹夜蛾的生物农药制剂及其制备方法
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
WO2014151705A1 (en) * 2013-03-15 2014-09-25 Ansun Biopharma, Inc. Methods for preparing injectable protein microparticle suspensions
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
KR102465025B1 (ko) * 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2016044656A1 (en) 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
DE102014114403A1 (de) * 2014-10-02 2016-04-07 Gerresheimer Regensburg Gmbh Stopfen zum Aufsetzen auf ein Anschlusselement einer medizinischen Spritze
ES2947818T3 (es) 2014-11-18 2023-08-21 Ascendis Pharma Endocrinology Div A/S Nuevos profármacos poliméricos de la HCh
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
CN104523659A (zh) * 2015-01-19 2015-04-22 陈长潭 一种胸腺五肽吸入粉雾剂及其制备方法
CN106924715A (zh) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 特利加压素脂质体及其制备方法
CN105963257B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN106075403A (zh) * 2016-06-12 2016-11-09 暨南大学 一种胰岛素口服硒纳米制剂及其制备方法
ES2947312T3 (es) 2016-07-01 2023-08-04 Univ Leland Stanford Junior Conjugados para la edición dirigida de la superficie celular
KR20180007322A (ko) * 2016-07-11 2018-01-22 주식회사 삼양바이오팜 고분자 마이크로스피어의 연속 제조방법 및 이를 위한 장치
EP3484450A4 (en) * 2016-07-18 2020-04-01 Tissuegen, Inc. METHODS AND COMPOSITIONS FOR MAINTAINING THE CONFORMATION AND STRUCTURAL INTEGRITY OF BIOMOLECULES
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
DE102017104277A1 (de) * 2017-03-01 2018-09-06 Lts Lohmann Therapie-Systeme Ag Transmukosales Verabreichungssystem für Idebenon
CA3073325A1 (en) 2017-08-25 2019-02-28 AZ Solutions LLC System and method for wound treatment and irrigation
US20210252048A1 (en) * 2017-08-25 2021-08-19 AZ solutions, LLC Treatment of lung and airway diseases and disorders
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EP3684338A4 (en) 2017-09-22 2021-06-23 Otitopic Inc. DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE
JP7462560B2 (ja) 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
CN108853492A (zh) * 2018-07-25 2018-11-23 中国医学科学院生物医学工程研究所 治疗自身性免疫疾病的疫苗佐剂及其应用
US20220133630A1 (en) * 2018-10-19 2022-05-05 Ac Pharmaceuticals Co., Ltd. Preparation method of sustained-release microparticles
CN109678964B (zh) * 2018-12-21 2022-02-25 陕西师范大学 一种利托菌素磁珠、制备方法及其应用
EP3934625A1 (en) 2019-03-04 2022-01-12 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
US11419910B1 (en) * 2019-05-10 2022-08-23 Guy J. Guidry Treatment of dermatitis and athlete's foot
CN110664758B (zh) * 2019-10-15 2021-11-30 无锡市人民医院 Pai-cpt还原响应型双药递送纳米粒子的制备方法
CN110923628B (zh) * 2019-11-06 2021-11-26 南京理工大学 一种新型表面团簇分子的制备方法
WO2021151005A1 (en) * 2020-01-22 2021-07-29 Ansun Biopharma, Inc. Inhaled das181 to treat cancer in the lung
CN115916213A (zh) * 2020-05-28 2023-04-04 胡建倧 用于治疗SARS-CoV-2的组合物和方法
AU2021342298A1 (en) * 2020-09-14 2023-05-18 Zhuhai Beihai Biotech Co., Ltd. Formulations of cabazitaxel
CN112472664B (zh) * 2020-11-17 2022-02-25 中国矿业大学 一种基因靶向治疗的纳米马达-水凝胶体系制备方法
CN118382453A (zh) * 2021-11-02 2024-07-23 安迅生物制药公司 Das181变体组合物
CN113893384B (zh) * 2021-11-08 2022-06-21 山东省科学院生物研究所 一种交联壳聚糖微球及其在创面止血修复材料中的应用
CN114377200B (zh) * 2022-01-12 2023-03-24 北京阅色科技发展中心(有限合伙) 面部注射填充用可生物降解亲水高分子微球及制备方法
CN114652734A (zh) * 2022-03-31 2022-06-24 李红梦 一种祛痘的药物组合物及其制备方法
CN115770232A (zh) * 2022-10-28 2023-03-10 苏州大学 一种地佐辛缓释微球及其制备方法
CN117654445B (zh) * 2023-10-20 2026-03-27 广州康盛生物科技股份有限公司 重组蛋白a冻干粉及制备方法
CN117654361A (zh) * 2023-10-31 2024-03-08 武汉工程大学 一种控制羟苯磺酸钙原料粒径的方法
CN120514914B (zh) * 2025-07-22 2025-09-23 成都恒美盛生物科技有限公司 一种高浓高粘可注射软组织填充材料及其制备方法和用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3439089A (en) * 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US5052558A (en) * 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) * 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5323907A (en) * 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ES2215207T3 (es) * 1993-03-09 2004-10-01 Baxter International Inc. Microparticulas de macromoleculas y metodos de produccion.
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
AU3905697A (en) * 1996-08-09 1998-03-06 Suzanne M. Gibson Heat-stable protein microparticles and no-shear process for producing same
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB9910975D0 (en) 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
CN1729013B (zh) 2002-11-22 2012-10-03 耐百生物制药有限公司 广谱抗病毒化合物、药物制剂及其用途
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
WO2005035088A2 (en) * 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
CN1909921B (zh) * 2003-11-10 2012-09-26 Uab研究基金会 减少细菌携带和中枢神经系统侵害的组合物及其使用方法
US7651694B2 (en) * 2004-02-13 2010-01-26 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1753404A1 (en) 2004-05-12 2007-02-21 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
EP1981483A1 (en) 2006-01-24 2008-10-22 Nexbio, Inc. Technology for preparation of macromolecular microspheres
CN103784408A (zh) 2007-07-24 2014-05-14 安迅生物制药公司 用于制备微粒的技术

Also Published As

Publication number Publication date
BRPI0706947A8 (pt) 2019-01-29
JP6063239B2 (ja) 2017-01-18
KR20170091184A (ko) 2017-08-08
US10583086B2 (en) 2020-03-10
RU2012131203A (ru) 2014-01-20
CN104758253A (zh) 2015-07-08
KR101501780B1 (ko) 2015-03-16
JP2009524667A (ja) 2009-07-02
US20200197310A1 (en) 2020-06-25
KR20200052386A (ko) 2020-05-14
CA2932997C (en) 2019-07-30
EP1981483A1 (en) 2008-10-22
JP2013064010A (ja) 2013-04-11
KR101787939B1 (ko) 2017-10-18
IL193001A (en) 2015-08-31
US20150290134A1 (en) 2015-10-15
ZA200807133B (en) 2009-05-27
WO2007114881A1 (en) 2007-10-11
US20180071219A1 (en) 2018-03-15
HK1210720A1 (en) 2016-05-06
RU2464973C2 (ru) 2012-10-27
US20070190163A1 (en) 2007-08-16
KR20080090525A (ko) 2008-10-08
RU2008134282A (ru) 2010-02-27
BRPI0706947A2 (pt) 2011-04-12
AU2007233349A1 (en) 2007-10-11
CA2639925A1 (en) 2007-10-11
CA2639925C (en) 2016-07-12
CA2932997A1 (en) 2007-10-11
KR20150001844A (ko) 2015-01-06
US20140134150A1 (en) 2014-05-15
KR20160147067A (ko) 2016-12-21
US20100166874A1 (en) 2010-07-01
KR102180849B1 (ko) 2020-11-20
CN101404980A (zh) 2009-04-08
KR102109867B1 (ko) 2020-05-13
IL240268A0 (en) 2015-09-24
JP5457680B2 (ja) 2014-04-02
US8623419B2 (en) 2014-01-07
BRPI0706947B1 (pt) 2021-02-09
RU2628807C2 (ru) 2017-08-22
US20120116062A1 (en) 2012-05-10
IL193001A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
BRPI0706947A8 (pt) método de preparação de uma composição à base de proteína, e, método de preparação de micropartículas baseadas em proteínas
BRPI0613429A2 (pt) inibidores de histona desacetilase
WO2009015286A3 (en) Technology for the preparation of microparticles
BR112013015162A2 (pt) processo para preparar uma composição de revestimento anti-incrustante, composição de revestimento anti-incrustante e seu uso
WO2007012979A3 (en) Polylactide compositions and uses thereof
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
AR064254A1 (es) Maiz extraido con solvente
BRPI0606876A2 (pt) diiodometil p-tolil sulfona sob a forma de uma dispersão de particulados em um solvente lìquido, em combinação com um ativo anticaspa
BR112015023399A2 (pt) inibidores de hdac
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
BR112014033008A2 (pt) conjunto de parâmetros de vídeo para hevc e extensões
BRPI0717404A2 (pt) Processo para produzir polímero modifcado, polímero modificado obtido pelo processo e composição de borracha de borracha contendo o mesmo
BRPI0506843A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
BRPI0816550A2 (pt) Sistema de acesso a um equipamento pessoal de informatica a bordo de um aeronave, processo de acesso a um equipamento pessoal de informatica a bordo de uma aeronave e aeronave
BR112012024784A2 (pt) fluido para reparo de poços
BR112014007332A2 (pt) mensagens de conclusão agregada em uma interface de banda lateral
BRPI0815750A2 (pt) processo para recuperar um solvente orgânico e um etanol orgânico de uma mistura de etanol/água.
BRPI0809987A2 (pt) Método para interconexão de aplicativos de software discrepantes, de estender dos serviços fornecidos pelo esb, sistema e produto de programa de computador
BR112014032514A2 (pt) cartão de chip e método de produção de um cartão de chip
BR112015028740A2 (pt) processo para preparar dicarbamatos de 1,4:3,6-dianidroexitóis, composto químico precursor, composto químico derivado a partir de pelo menos um dos compostos químicos precursores, e, método de preparação de um composto químico derivado a partir de pelo menos um dos compostos químicos precursores
UY30790A1 (es) Combinacion de dos agentes antiparasitarios, en particular un derivado de 1-aril-4-ciclopropilpirazol y un agente antihelmintico y aplicaciones
BR112013031001A2 (pt) método, programa de computador e aparelho

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ANSUN BIOPHARMA, INC. (US)

B25G Requested change of headquarter approved

Owner name: ANSUN BIOPHARMA, INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.7 NA RPI NO 2563 DE 18/02/2020 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/01/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2811 DE 19-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.